Profil
Robert Bender is the founder of Immune Control, Inc. (founded in 2001).
He is currently the Chairman of Nometics, Inc. and has previously served as the Chairman & Chief Executive Officer of sGC Pharma, Inc.
Postes actifs de Robert Bender
| Sociétés | Poste | Début |
|---|---|---|
Nometics, Inc.
 Nometics, Inc. Pharmaceuticals: MajorHealth Technology Nometics, Inc. operates as a specialty pharmaceutical company. It focuses on the treatment of cancer through the restoration of the nitric oxide signaling pathway. The company is headquartered in Toronto, Canada. | Président | - |
Anciens postes connus de Robert Bender
| Sociétés | Poste | Fin |
|---|---|---|
Immune Control, Inc.
 Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Fondateur | - |
sGC Pharma, Inc.
 sGC Pharma, Inc. Pharmaceuticals: MajorHealth Technology sGC Pharma, Inc. developed, manufactured and marketed pharmaceutical products. It developed a drug to improve cognition and memory in patients with Alzheimer's disease. The company was founded in 2007 and headquartered in Wellesley, MA. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Nometics, Inc.
Nometics, Inc. Pharmaceuticals: MajorHealth Technology Nometics, Inc. operates as a specialty pharmaceutical company. It focuses on the treatment of cancer through the restoration of the nitric oxide signaling pathway. The company is headquartered in Toronto, Canada. | Health Technology |
sGC Pharma, Inc.
sGC Pharma, Inc. Pharmaceuticals: MajorHealth Technology sGC Pharma, Inc. developed, manufactured and marketed pharmaceutical products. It developed a drug to improve cognition and memory in patients with Alzheimer's disease. The company was founded in 2007 and headquartered in Wellesley, MA. | Health Technology |
Immune Control, Inc.
Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Health Technology |
